Werkgroep Cardiologische centra Nederland

SPIRE-2 (Completed)

The Evaluation of Bococizumab (PF-04950615) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects (SPIRE-2)
Medicine
Bococizumab
Population
ASCVD
Phase
III
Starting year
2014
More information
ClinicalTrials.gov

Director of Study

dr. J. Schaap (Cardioloog)
Breda, Amphia Ziekenhuis

SPIRE-2: News